Eragny-sur-Oise (France), September 9, 2015 – SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, announces today that it has appointed Thierry Lambert as Chief Financial Officer (CFO).
Thierry Lambert’s main task will be to handle the Company’s finances and administrative affairs and he will work closely with executive management. Safe Orthopaedics will benefit from Thierry’s international vision and experience of running the finances of a listed group as the company pursues strong growth and expansion into international markets.
Thierry Lambert, 37, has 15 years’ experience of financial functions, including at the Naturex group, which he joined in 2009 as Corporate Finance Manager and where he then became Group CFO. Previously, Thierry held various positions at CIT and PricewaterhouseCoopers in the United Kingdom where he worked on mergers & acquisitions and leveraged finance. He is a qualified UK chartered accountant and also holds an MBA from INSEAD.
In 2014, Thierry Lambert was ranked by DAF Magazine as one of the 50 most influential CFOs in France.
“We are delighted to welcome Thierry Lambert to our team”, said Yves Vignancour, Chief Executive Officer of Safe Orthopaedics.“His international experience and strong financial expertise gained at a leading international group will be crucial assets for us as we look to step up our international expansion in Europe, the United States and around the world.”
Next financial release: 1st half 2015 results on Monday September 28, 2015 (after market close)
About Safe Orthopaedics
Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the company’s CE-marked and FDA-approved SteriSpineTM kits are already being marketed in 12 countries, in Europe and the United States. They are being rapidly adopted by surgeons throughout the world, with nearly 1,000 procedures performed in 2014 and 1,143 in the first half of 2015 alone. The company is based at Eragny‑sur‑Oise (France), and has 33 employees and a US subsidiary.